Developer docs
API playgroundTry for free, no card

Search company profiles

Novotech

Full company profile

uuid000083i

Namestring
Novotech
Legal namestring
Novotech Health Holdings
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Novotech is a privately held, full-service clinical research organization (CRO) founded in 1992, originally headquartered in Sydney, Australia, and repositioned with a new global headquarters in Singapore as of January 2026 under incoming CEO Dr. Anand Tharmaratnam. The company delivers integrated biotech clinical trial services across all phases (Phase I-IV) and therapeutic areas — including oncology, liver disease, infectious diseases and vaccines, orphan/rare diseases, and pharmacometrics — to biotechnology companies and small-to-mid-sized pharmaceutical firms globally. Novotech operates 30+ offices across Asia-Pacific, North America, and Europe with over 2,300 full-time employees, maintaining a network of 5,000+ trial sites, 4,950+ investigators, and a track record of 4,450+ completed trials across 50+ countries with 60+ drugs brought to market.

The company's service portfolio spans medical and regulatory consulting, clinical operations and project management, biometrics and data management, real-world data analytics, bioanalytical laboratory services, and a flexible clinical staffing platform called FLEX, complemented by wholly owned subsidiaries including Acrostar (a Site Management Organization founded in 2013) and BioDesk (regulatory consulting). Novotech holds a distinctive regulatory position as the operator of Australia's first privately owned commercial Institutional Biosafety Committee certified by the Office of the Gene Technology Regulator (OGTR), enabling GMO clinical trial certification, and leverages Australia's 43.5% R&D cash refund scheme to attract early-phase studies. In February 2026, the company entered a multi-trial licensing agreement with ObvioHealth to deploy the ObvioGo digital trial platform (eConsent, ePRO/eCOA, remote/hybrid assessments) across its programs.

Novotech monetizes through project-based, quote-driven professional services contracts with biotech and pharma sponsors, with pricing varying by trial complexity, phase, therapeutic area, and geography. The company is majority-backed by TPG Capital Asia (via its Asia VIII fund), with Singapore sovereign wealth funds GIC and Temasek taking stakes in March 2025 at a valuation exceeding A$3 billion, following a US$760M financing in January 2022. The go-to-market is direct enterprise sales with relationship-based engagement across APAC, Europe, and North America, supported by industry-leading recognition including 19 consecutive years of Frost & Sullivan CRO Company of the Year awards.

Short descriptiontext

Novotech is a privately held, full-service clinical research organization (CRO) serving biotechnology and small-to-mid-sized pharmaceutical companies globally, with 2,300+ employees across Asia-Pacific, North America, and Europe, delivering clinical trial management across all phases and therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, biotech clinical trials, regulatory affairs consulting, patient recruitment services, pharmacovigilance services
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Engineering, Accounting, Research, Management8700
Product category
Clinical Research Organization (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Organization Services
TypeProfessional Services
Description

Project-based CRO services providing full-service clinical trial management across Phase I to Phase IV, including clinical operations, project management, site management, biometrics, data management, regulatory affairs, medical monitoring, safety services, and central lab services. Revenue generated through individual project contracts with biotech and pharmaceutical sponsors.

novotech-cro.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Novotech is a globally recognized full-service clinical research organization (CRO) that provides integrated clinical trial services for biotech and small-to-mid-sized pharmaceutical companies across all phases (Phase I to Phase IV) and therapeutic areas. Service offerings span clinical operations, project management, biometrics, data management, regulatory affairs, medical monitoring, safety/pharmacovigilance, central lab services, site management (via Acrostar SMO), regulatory consulting (via BioDesk), and clinical staffing (via FLEX), delivered through 30+ offices across Asia-Pacific, North America and Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4,450+ clinical trials completed across 50+ countries
+4 more records
Product overview1 text field

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that guides biotech and small-to-mid-sized pharmaceutical companies through all phases of drug development. The company operates across Asia-Pacific, North America, and Europe through 30+ offices, with partnerships spanning 5,000+ trial sites and 4,950+ investigators. The portfolio is organized around a core set of service modules — Medical and Regulatory Consulting, Patient Recruitment and Site Selection, Early Phase Trials in Australia, Clinical Operations and Project Management, Biometrics and Data Management, Real World Data, Laboratory Services, and FLEX staffing solutions — supplemented by a specialized SMO division (Acrostar) and a regulatory consulting subsidiary (BioDesk). Novotech's therapeutic expertise spans Oncology, Pharmacometrics, Drug Development Consulting, GMO Solutions, Liver Disease, Infectious Diseases and Vaccines, and Orphan and Rare Diseases. The company has conducted 4,450+ clinical trials across 50+ countries, bringing 60+ drugs to market. Recent strategic expansions include radiopharmaceutical trials and partnerships with companies like Tune Therapeutics and Biostar. Notable acquisitions include EastHORN (European CRO, 2023) and NCGS (US CRO, 2022), with a US$760M financing round completed in January 2022 valuing the company at ~US$3 billion.

Product and service17 records
1Medical and Regulatory Consulting
CategoryCRO consulting service
Description

Full range of pre-clinical support, regulatory affairs, medical, and pharmacovigilance consulting services to guide biotech companies through clinical development and approval processes.

2Patient Recruitment and Site Selection
CategoryCRO service
Description

Uses years of experience, in-country knowledge, and real-world big data to identify and propose the best-performing sites for clinical trials, accelerating enrollment timelines.

3Early Phase Trials in Australia
CategoryCRO service
Description

Australia-based early-phase clinical trial services leveraging the country's streamlined regulatory pathway and 43.5% R&D cash refund scheme, enabling faster study initiation and cost savings.

4Clinical Operations and Project Management
CategoryCRO service
Description

Streamlined and integrated clinical trial services delivered by a dedicated team of professionals covering project management, clinical monitoring, and patient recruitment across all trial phases.

5Acrostar SMO Division
CategorySub-brand / SMO service
Description

Site Management Organization (SMO) services operating across Asia-Pacific including China, Taiwan, and South Korea, providing clinical trial site management services for sponsors.

6Biometrics and Data Management
CategoryCRO service
Description

Asia-Pacific internal biometrics and statistical programming team delivering biostatistics services including statistical planning, analysis, regulatory submission, and reporting for clinical trials.

7Real World Data
CategoryCRO service
Description

Service leveraging large-scale observational real-world data to support site selection, patient stratification, adaptive trial design, and evidence generation across clinical programs.

8Laboratory Services
CategoryCRO service
Description

Bioanalytical services assisting customers at every stage of molecule development, covering preclinical through clinical phases with comprehensive laboratory support.

9FLEX Clinical Staffing Solution
CategoryCRO service
Description

Clinical staffing solution offering a predictable budget plan for ongoing clinical pipelines and flexibility to scale up or down, integrating talent, processes, technology, and information infrastructure for sponsors.

10Oncology CRO Services
CategoryTherapeutic-area CRO service
Description

Global oncology-focused clinical research services for biotechnology companies, supporting trial design, site selection, and execution across solid tumors and hematologic malignancies.

11Liver Disease CRO Services
CategoryTherapeutic-area CRO service
Description

Specialized liver disease clinical trial services covering Hepatitis B and C, HCC, NASH, NAFLD, and liver transplantation; over 200 liver disease clinical trials conducted over 25 years.

12Infectious Diseases and Vaccines CRO Services
CategoryTherapeutic-area CRO service
Description

Comprehensive CRO services for infectious diseases and vaccine trials, including feasibility assessments, protocol design, and patient recruitment strategies (adult and pediatric) across HIV, influenza, Hepatitis B and C, malaria, CMV, RSV, and COVID-19.

13Orphan and Rare Disease CRO Services
CategoryTherapeutic-area CRO service
Description

Rare disease clinical research services with specialized expertise in patient recruitment and registry access; over 20 trials conducted across indications including acromegaly, cystic fibrosis, DMD, Gaucher disease, and PNH.

14Pharmacometric Services
CategoryTherapeutic-area CRO service
Description

Pharmacometric team assisting across all clinical study phases and designs including first-in-human, single ascending dose, multiple ascending dose, drug-drug interaction, food effect, and special population studies.

15Drug Development Consulting
CategoryTherapeutic-area CRO service
Description

Full-service global product development and strategic regulatory group providing comprehensive lab-to-launch program development services including clinical and regulatory strategy.

16GMO Solutions
CategorySpecialized CRO service
Description

Service enabling sponsors to obtain and retain certification for clinical trials using genetically modified organisms (GMOs) in Australia via Novotech's privately-owned commercial Institutional Biosafety Committee (IBC), certified by OGTR.

17BioDesk Regulatory Consulting
CategorySub-brand / consulting service
Description

Wholly-owned clinical and regulatory consulting subsidiary providing biotech companies with regulatory expert support for clinical and drug development planning, GMP product preparation, GLP toxicology coordination, and IND/NDA submissions to FDA and EMA.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Marvel Biosciences selected Novotech as CRO for its Phase I clinical trial of MB-204, a neuroactive adenosine A2A antagonist for neurodevelopmental disorders including Rett syndrome, Fragile X syndrome, autism, and depression. Trial conducted in Australia leveraging favorable regulatory environment.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-02-24
Description

Novotech entered a strategic multi-trial licensing agreement with ObvioHealth to license the ObvioGo platform across multiple clinical trials. The enterprise platform combines eConsent, ePRO/eCOA, and remote/hybrid assessments, enabling Novotech teams to reuse standardized digital workflows.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

Novotech serves as CRO for Primmune's Phase 2 neoadjuvant efficacy study (PRTX007-003) of PRTX007, a novel orally administered TLR7 agonist immunotherapy for solid tumors. Study conducted entirely in Australia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-14
Description

Strategic partnership focusing on a groundbreaking clinical trial program advancing epigenome editing therapy for chronic hepatitis B (CHB). The partnership combines Novotech's regulatory, operational, and clinical expertise with Tune's innovative TEMPO gene调节 platform. Awarded Citeline CRO Partnership of the Year 2025.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-03-19
Description

Partnership to strengthen clinical trial capabilities in Korea, enhancing Novotech's presence and operational capacity in the Korean market.

6Beijing Biostar Pharmaceuticals
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Strategic partnership established following Biostar's successful listing on Hong Kong Stock Exchange. Collaboration aims to accelerate clinical research and support Biostar's development of innovative oncology drugs, leveraging both companies' expertise to expand international presence.

businesswireindia.com
7EastHORN Clinical Services
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-09
Description

Novotech acquired EastHORN, a European CRO headquartered in Poland, as part of its global expansion program. The acquisition enhanced Novotech's ability to provide in-country clinical development services across Europe, North America, and Asia-Pacific, integrating EastHORN's European expertise.

globenewswire.com
8NCGS
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-05
Description

Novotech acquired US CRO NCGS to expand global clinical trial capabilities, particularly supporting biotechs in the US and APAC regions. The move integrated US expertise and infrastructure for later-phase global studies.

biospectrumasia.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

The world's largest CRO and a Novotech competitor for global biotech and pharma trial work. Novotech's incoming CEO spent 23 years at IQVIA, underscoring IQVIA as the standard against which Novotech benchmarks scale and preferred-provider positioning.

TypeDirect peer
Description

Top-tier global CRO formed via the PRA Health Sciences merger, with broad Phase I–IV capabilities and a strong biotech sponsor book. Directly competes with Novotech for global biotech trial outsourcing and biotech preferred-provider mandates.

TypeBroad incumbent
Description

Large global CRO spun out of Labcorp with end-to-end clinical development plus central lab services. Overlaps with Novotech on clinical operations, biometrics, and central lab work, particularly for biotech sponsors seeking late-phase global capacity.

TypeDirect peer
Description

China-headquartered full-service CRO with growing international presence. Closest APAC-headquartered peer to Novotech, competing for cross-border biotech trials and providing a direct benchmark on China-based clinical operations.

TypeBroad incumbent
Description

Asia-based CRO/CDMO offering clinical and preclinical services alongside broader drug development capabilities. Overlaps with Novotech's clinical operations in China and APAC, and is a comparable regional alternative for biotech sponsors.

TypeDirect peer
Description

PE-owned global CRO with deep biotech sponsor relationships and full Phase I–IV services. Competes head-to-head with Novotech for mid-sized biotech trial outsourcing and represents a comparable ownership archetype under PE ownership.

TypeDirect peer
Description

Mid-sized global CRO with a biotech-focused business model emphasizing operational excellence and high-quality data. Closest comparable in terms of sponsor-segment targeting, with disclosed financials that benchmark Novotech's organic growth profile.

TypeDirect peer
Description

Clinical and commercial services provider serving biotech and pharma sponsors globally. Overlaps with Novotech on full-service clinical operations and is a directly comparable full-service peer for biotech outsourcing decisions.

TypeEmerging player
Description

Mid-sized global CRO focused on complex clinical trials across multiple therapeutic areas. Comparable to Novotech in size and biotech-segment positioning, providing a useful mid-tier benchmark for trial volume and therapeutic mix.

TypeBroad incumbent
Description

Large CRO with a strong preclinical and discovery franchise plus growing clinical services. Comparable to Novotech on the early-phase/biopharma-services side, particularly for biotech sponsors seeking integrated discovery-to-clinical support.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novotech

Clinical Research Organization (CRO) Servicesnovotech-cro.com

Novotech is a privately held, full-service clinical research organization (CRO) serving biotechnology and small-to-mid-sized pharmaceutical companies globally, with 2,300+ employees across Asia-Pacific, North America, and Europe, delivering clinical trial management across all phases and therapeutic areas.

What Novotech does

Novotech is a privately held, full-service clinical research organization (CRO) founded in 1992, originally headquartered in Sydney, Australia, and repositioned with a new global headquarters in Singapore as of January 2026 under incoming CEO Dr. Anand Tharmaratnam. The company delivers integrated biotech clinical trial services across all phases (Phase I-IV) and therapeutic areas — including oncology, liver disease, infectious diseases and vaccines, orphan/rare diseases, and pharmacometrics — to biotechnology companies and small-to-mid-sized pharmaceutical firms globally. Novotech operates 30+ offices across Asia-Pacific, North America, and Europe with over 2,300 full-time employees, maintaining a network of 5,000+ trial sites, 4,950+ investigators, and a track record of 4,450+ completed trials across 50+ countries with 60+ drugs brought to market.

The company's service portfolio spans medical and regulatory consulting, clinical operations and project management, biometrics and data management, real-world data analytics, bioanalytical laboratory services, and a flexible clinical staffing platform called FLEX, complemented by wholly owned subsidiaries including Acrostar (a Site Management Organization founded in 2013) and BioDesk (regulatory consulting). Novotech holds a distinctive regulatory position as the operator of Australia's first privately owned commercial Institutional Biosafety Committee certified by the Office of the Gene Technology Regulator (OGTR), enabling GMO clinical trial certification, and leverages Australia's 43.5% R&D cash refund scheme to attract early-phase studies. In February 2026, the company entered a multi-trial licensing agreement with ObvioHealth to deploy the ObvioGo digital trial platform (eConsent, ePRO/eCOA, remote/hybrid assessments) across its programs.

Novotech monetizes through project-based, quote-driven professional services contracts with biotech and pharma sponsors, with pricing varying by trial complexity, phase, therapeutic area, and geography. The company is majority-backed by TPG Capital Asia (via its Asia VIII fund), with Singapore sovereign wealth funds GIC and Temasek taking stakes in March 2025 at a valuation exceeding A$3 billion, following a US$760M financing in January 2022. The go-to-market is direct enterprise sales with relationship-based engagement across APAC, Europe, and North America, supported by industry-leading recognition including 19 consecutive years of Frost & Sullivan CRO Company of the Year awards.

Novotech firmographics

Firmographics
Name
Novotech
Legal name
Novotech Health Holdings
Website
https://novotech-cro.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Novotech is a privately held, full-service clinical research organization (CRO) serving biotechnology and small-to-mid-sized pharmaceutical companies globally, with 2,300+ employees across Asia-Pacific, North America, and Europe, delivering clinical trial management across all phases and therapeutic areas.
Ownership category
akta.pro rank

Novotech industry classification

Industry
Product category
Clinical Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Engineering, Accounting, Research, Management (8700)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Clinical research services
  • Biotech clinical trials
  • Regulatory affairs consulting
  • Patient recruitment services
  • Pharmacovigilance services

Where Novotech is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices3 records

Markets served

Novotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Clinical Research Organization Services: Project-based CRO services providing full-service clinical trial management across Phase I to Phase IV, including clinical operations, project management, site management, biometrics, data management, regulatory affairs, medical monitoring, safety services, and central lab services. Revenue generated through individual project contracts with biotech and pharmaceutical sponsors.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Novotech product offering

Product offering

Core offering

Novotech is a globally recognized full-service clinical research organization (CRO) that provides integrated clinical trial services for biotech and small-to-mid-sized pharmaceutical companies across all phases (Phase I to Phase IV) and therapeutic areas. Service offerings span clinical operations, project management, biometrics, data management, regulatory affairs, medical monitoring, safety/pharmacovigilance, central lab services, site management (via Acrostar SMO), regulatory consulting (via BioDesk), and clinical staffing (via FLEX), delivered through 30+ offices across Asia-Pacific, North America and Europe.

Product overview

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that guides biotech and small-to-mid-sized pharmaceutical companies through all phases of drug development. The company operates across Asia-Pacific, North America, and Europe through 30+ offices, with partnerships spanning 5,000+ trial sites and 4,950+ investigators. The portfolio is organized around a core set of service modules — Medical and Regulatory Consulting, Patient Recruitment and Site Selection, Early Phase Trials in Australia, Clinical Operations and Project Management, Biometrics and Data Management, Real World Data, Laboratory Services, and FLEX staffing solutions — supplemented by a specialized SMO division (Acrostar) and a regulatory consulting subsidiary (BioDesk). Novotech's therapeutic expertise spans Oncology, Pharmacometrics, Drug Development Consulting, GMO Solutions, Liver Disease, Infectious Diseases and Vaccines, and Orphan and Rare Diseases. The company has conducted 4,450+ clinical trials across 50+ countries, bringing 60+ drugs to market. Recent strategic expansions include radiopharmaceutical trials and partnerships with companies like Tune Therapeutics and Biostar. Notable acquisitions include EastHORN (European CRO, 2023) and NCGS (US CRO, 2022), with a US$760M financing round completed in January 2022 valuing the company at ~US$3 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical and Regulatory Consulting Full range of pre-clinical support, regulatory affairs, medical, and pharmacovigilance consulting services to guide biotech companies through clinical development and approval processes.
  • Patient Recruitment and Site Selection Uses years of experience, in-country knowledge, and real-world big data to identify and propose the best-performing sites for clinical trials, accelerating enrollment timelines.
  • Early Phase Trials in Australia Australia-based early-phase clinical trial services leveraging the country's streamlined regulatory pathway and 43.5% R&D cash refund scheme, enabling faster study initiation and cost savings.
  • Clinical Operations and Project Management Streamlined and integrated clinical trial services delivered by a dedicated team of professionals covering project management, clinical monitoring, and patient recruitment across all trial phases.
  • Acrostar SMO Division Site Management Organization (SMO) services operating across Asia-Pacific including China, Taiwan, and South Korea, providing clinical trial site management services for sponsors.
  • Biometrics and Data Management Asia-Pacific internal biometrics and statistical programming team delivering biostatistics services including statistical planning, analysis, regulatory submission, and reporting for clinical trials.
  • Real World Data Service leveraging large-scale observational real-world data to support site selection, patient stratification, adaptive trial design, and evidence generation across clinical programs.
  • Laboratory Services Bioanalytical services assisting customers at every stage of molecule development, covering preclinical through clinical phases with comprehensive laboratory support.
  • FLEX Clinical Staffing Solution Clinical staffing solution offering a predictable budget plan for ongoing clinical pipelines and flexibility to scale up or down, integrating talent, processes, technology, and information infrastructure for sponsors.
  • Oncology CRO Services Global oncology-focused clinical research services for biotechnology companies, supporting trial design, site selection, and execution across solid tumors and hematologic malignancies.
  • Liver Disease CRO Services Specialized liver disease clinical trial services covering Hepatitis B and C, HCC, NASH, NAFLD, and liver transplantation; over 200 liver disease clinical trials conducted over 25 years.
  • Infectious Diseases and Vaccines CRO Services Comprehensive CRO services for infectious diseases and vaccine trials, including feasibility assessments, protocol design, and patient recruitment strategies (adult and pediatric) across HIV, influenza, Hepatitis B and C, malaria, CMV, RSV, and COVID-19.
  • Orphan and Rare Disease CRO Services Rare disease clinical research services with specialized expertise in patient recruitment and registry access; over 20 trials conducted across indications including acromegaly, cystic fibrosis, DMD, Gaucher disease, and PNH.
  • Pharmacometric Services Pharmacometric team assisting across all clinical study phases and designs including first-in-human, single ascending dose, multiple ascending dose, drug-drug interaction, food effect, and special population studies.
  • Drug Development Consulting Full-service global product development and strategic regulatory group providing comprehensive lab-to-launch program development services including clinical and regulatory strategy.
  • GMO Solutions Service enabling sponsors to obtain and retain certification for clinical trials using genetically modified organisms (GMOs) in Australia via Novotech's privately-owned commercial Institutional Biosafety Committee (IBC), certified by OGTR.
  • BioDesk Regulatory Consulting Wholly-owned clinical and regulatory consulting subsidiary providing biotech companies with regulatory expert support for clinical and drug development planning, GMP product preparation, GLP toxicology coordination, and IND/NDA submissions to FDA and EMA.

Quantifiable outcome

  • 4,450+ clinical trials completed across 50+ countries
  • +4 more outcomes

Companies that use Novotech

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Novotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Novotech partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered strategic and core.

  • Marvel Biosciences Corp.strategicStrategic or Co-development Partner · 25 March 2026Marvel Biosciences selected Novotech as CRO for its Phase I clinical trial of MB-204, a neuroactive adenosine A2A antagonist for neurodevelopmental disorders including Rett syndrome, Fragile X syndrome, autism, and depression. Trial conducted in Australia leveraging favorable regulatory environment.
  • ObvioHealthstrategicTechnology or Integration · 24 February 2026Novotech entered a strategic multi-trial licensing agreement with ObvioHealth to license the ObvioGo platform across multiple clinical trials. The enterprise platform combines eConsent, ePRO/eCOA, and remote/hybrid assessments, enabling Novotech teams to reuse standardized digital workflows.
  • Primmune TherapeuticsstrategicStrategic or Co-development Partner · 26 January 2026Novotech serves as CRO for Primmune's Phase 2 neoadjuvant efficacy study (PRTX007-003) of PRTX007, a novel orally administered TLR7 agonist immunotherapy for solid tumors. Study conducted entirely in Australia.
  • Tune TherapeuticscoreStrategic or Co-development Partner · 14 May 2025Strategic partnership focusing on a groundbreaking clinical trial program advancing epigenome editing therapy for chronic hepatitis B (CHB). The partnership combines Novotech's regulatory, operational, and clinical expertise with Tune's innovative TEMPO gene调节 platform. Awarded Citeline CRO Partnership of the Year 2025.
  • Kyungpook National University HospitalstrategicStrategic or Co-development Partner · 19 March 2025Partnership to strengthen clinical trial capabilities in Korea, enhancing Novotech's presence and operational capacity in the Korean market.
  • Beijing Biostar PharmaceuticalsstrategicStrategic or Co-development Partner · 13 November 2024Strategic partnership established following Biostar's successful listing on Hong Kong Stock Exchange. Collaboration aims to accelerate clinical research and support Biostar's development of innovative oncology drugs, leveraging both companies' expertise to expand international presence.
  • EastHORN Clinical ServicescoreStrategic or Co-development Partner · 9 January 2023Novotech acquired EastHORN, a European CRO headquartered in Poland, as part of its global expansion program. The acquisition enhanced Novotech's ability to provide in-country clinical development services across Europe, North America, and Asia-Pacific, integrating EastHORN's European expertise.
  • NCGScoreStrategic or Co-development Partner · 5 May 2022Novotech acquired US CRO NCGS to expand global clinical trial capabilities, particularly supporting biotechs in the US and APAC regions. The move integrated US expertise and infrastructure for later-phase global studies.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Novotech competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: The world's largest CRO and a Novotech competitor for global biotech and pharma trial work. Novotech's incoming CEO spent 23 years at IQVIA, underscoring IQVIA as the standard against which Novotech benchmarks scale and preferred-provider positioning.
  • Fortrea (formerly Labcorp Drug Development / Covance): Large global CRO spun out of Labcorp with end-to-end clinical development plus central lab services. Overlaps with Novotech on clinical operations, biometrics, and central lab work, particularly for biotech sponsors seeking late-phase global capacity.
  • WuXi AppTec: Asia-based CRO/CDMO offering clinical and preclinical services alongside broader drug development capabilities. Overlaps with Novotech's clinical operations in China and APAC, and is a comparable regional alternative for biotech sponsors.
  • Charles River Laboratories: Large CRO with a strong preclinical and discovery franchise plus growing clinical services. Comparable to Novotech on the early-phase/biopharma-services side, particularly for biotech sponsors seeking integrated discovery-to-clinical support.

Direct peers

  • ICON plc: Top-tier global CRO formed via the PRA Health Sciences merger, with broad Phase I–IV capabilities and a strong biotech sponsor book. Directly competes with Novotech for global biotech trial outsourcing and biotech preferred-provider mandates.
  • Tigermed (Hangzhou Tigermed): China-headquartered full-service CRO with growing international presence. Closest APAC-headquartered peer to Novotech, competing for cross-border biotech trials and providing a direct benchmark on China-based clinical operations.
  • Parexel International: PE-owned global CRO with deep biotech sponsor relationships and full Phase I–IV services. Competes head-to-head with Novotech for mid-sized biotech trial outsourcing and represents a comparable ownership archetype under PE ownership.
  • Medpace: Mid-sized global CRO with a biotech-focused business model emphasizing operational excellence and high-quality data. Closest comparable in terms of sponsor-segment targeting, with disclosed financials that benchmark Novotech's organic growth profile.
  • Syneos Health: Clinical and commercial services provider serving biotech and pharma sponsors globally. Overlaps with Novotech on full-service clinical operations and is a directly comparable full-service peer for biotech outsourcing decisions.

Emerging players

  • Worldwide Clinical Trials: Mid-sized global CRO focused on complex clinical trials across multiple therapeutic areas. Comparable to Novotech in size and biotech-segment positioning, providing a useful mid-tier benchmark for trial volume and therapeutic mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Novotech social profiles

Digital presence

Novotech compliance and trust

Trust signal

Compliance2 records

Novotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novotech leadership team

Management profile

Number of profiles

Profiles9 records

Novotech subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Novotech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novotech M&A and investment

M&A and investment

M&A5 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novotech

What does Novotech do?

Novotech is a globally recognized full-service clinical research organization (CRO) that provides integrated clinical trial services for biotech and small-to-mid-sized pharmaceutical companies across all phases (Phase I to Phase IV) and therapeutic areas. Service offerings span clinical operations, project management, biometrics, data management, regulatory affairs, medical monitoring, safety/pharmacovigilance, central lab services, site management (via Acrostar SMO), regulatory consulting (via BioDesk), and clinical staffing (via FLEX), delivered through 30+ offices across Asia-Pacific, North America and Europe.

Is Novotech a public or private company?

Novotech is a private company. It is classified as private equity controlled and is currently operating.

When was Novotech founded?

Novotech was founded in 1992. It employs 1,001 to 5,000 people.

Where is Novotech based?

Novotech is headquartered in Singapore, Singapore, in the Asia region.

How does Novotech make money?

One revenue line is on record: clinical Research Organization Services.

Who are Novotech's main competitors?

Broad incumbents on record are IQVIA, Fortrea (formerly Labcorp Drug Development / Covance), WuXi AppTec and Charles River Laboratories. Direct peers are ICON plc, Tigermed (Hangzhou Tigermed), Parexel International, Medpace and Syneos Health. Worldwide Clinical Trials is listed as an emerging player.

Does Novotech have an API?

No public API is recorded for Novotech.

What industry is Novotech in?

Novotech's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8700.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmaTimesNovotech to acquire Agilex BiolabsNovotech agreed to acquire Agilex Biolabs, an Adelaide-based bioanalytical lab, from a Healius subsidiary. The deal adds Australian bioanalytical expertise to Novotech's Asia network and is subject to regulatory clearances. Novotech partners with over 5,000 trial sites.Pulse 2.0Novotech To Acquire Agilex Biolabs From Healius To Expand Australian Bioanalytical ServicesNovotech agreed to acquire Agilex Biolabs from Healius to expand its Australian bioanalytical laboratory services. The deal will add Agilex's Adelaide operations to Novotech's Asia-Pacific network, with financial terms undisclosed. Completion is subject to regulatory clearances, with no closing date set.Medical BuyerNovotech to acquire Agilex BiolabsNovotech agreed to acquire Agilex Biolabs, a bioanalytical laboratory in Adelaide, from Healius Limited. The deal adds Australian bioanalytical expertise to Novotech's Asia network, subject to regulatory clearances.FinancialContent Business PageNovotech to acquire Agilex BiolabsNovotech agreed to acquire Agilex Biolabs, a specialist bioanalytical laboratory in Adelaide, Australia, from a wholly owned subsidiary of Healius. The deal adds bioanalytical expertise to Novotech's existing laboratory network across Asia. Completion is subject to customary conditions, including regulatory clearances.The future of tradingHealius To Sell Agilex Biolabs To NovotechHealius Limited agreed to sell Agilex Biolabs to Novotech for an enterprise value of A$160 million, with completion anticipated in the second half of fiscal year 2027. The deal is expected to generate cash proceeds of about A$155 million.Novotech-CroNovotech to acquire Agilex BiolabsNovotech agreed to acquire Agilex Biolabs, a specialist bioanalytical laboratory in Adelaide, Australia, from a Healius subsidiary. The deal adds bioanalytical expertise to Novotech's Asia laboratory network, enabling better R&D support for biotech and pharma sponsors in Australia. Completion is subject to customary conditions, including regulatory clearances.BioSpaceNovotech Strengthens Presence in Japan with Opening of Tokyo OfficeNovotech opened a new Tokyo office to strengthen its presence in Japan, building on existing operations. The office will serve as a strategic hub for supporting Japanese biopharma companies in cross-border clinical trials. The move reflects Novotech's broader strategy to expand its global footprint as a CRO partner.AInvestThe hidden plumbing of drug development is being re-routedNovotech, a Singapore-backed contract research organization (CRO), opened a new office in Tokyo to capitalize on Japan's $84bn pharmaceutical market following regulatory reforms that eased clinical trial barriers. The expansion aims to bridge biotech innovation between Asia and global markets, leveraging Japan's aging population and faster trial approval processes compared to Europe. This move positions Novotech within the rapidly growing Asia-Pacific clinical trial sector, though it faces competition from larger integrated CROs and risks associated with biotech funding cycles.AijournNovotech Strengthens Presence in Japan with Opening of Tokyo OfficeNovotech, a global clinical research organization, has opened a new office in Tokyo to strengthen its presence in the Japanese market and support local biopharma companies. This strategic expansion aims to enhance cross-border clinical trial capabilities and facilitate international partnerships for clients seeking to expand beyond domestic development.FinancialContent Business PageNovotech Strengthens Presence in Japan with Opening of Tokyo OfficeNovotech has opened a new office in Tokyo to strengthen its clinical research operations and support for Japanese biopharma companies expanding into international markets. This strategic expansion aims to enhance local expertise and facilitate cross-border clinical trials connecting Asia-Pacific, the United States, and Europe.